Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus TADALAFIL.
ADCIRCA vs TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP)-mediated relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature.
10 mg orally three times daily.
Erectile dysfunction: 10-20 mg orally as needed, 30-60 minutes before sexual activity; maximum 1 dose per day. Benign prostatic hyperplasia: 5 mg orally once daily. Pulmonary arterial hypertension: 40 mg orally once daily.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Clinical Note
moderateTadalafil + Torasemide
"Tadalafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateTadalafil + Travoprost
"Tadalafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateTadalafil + Unoprostone
"Tadalafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateTadalafil + Hydrochlorothiazide
"Tadalafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life is 17.5 hours in healthy subjects; supports once-daily dosing and prolonged effect (up to 36 hours for erectile function).
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Primarily hepatic metabolism (CYP3A4); 36% excreted in urine (mainly metabolites), 61% in feces (mainly metabolites), <0.1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor